Lv3
246 积分 2025-05-12 加入
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
5天前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
5天前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
5天前
已完结
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
5天前
已完结
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
5天前
已完结
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
5天前
已完结
Carfilzomib-Associated Cardiovascular Adverse Events
18天前
已完结
Research progress in the treatment of slow transit constipation by traditional Chinese medicine
19天前
已完结
Multiple myeloma
1个月前
已完结
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE
2个月前
已关闭
皖公网安备34019202002308
